Diverse effects of clarithromycin and proposal of its clinical application for treating COVID-19 as a repurposing drug


Posted: 2021-09-11 19:00:00
Outbreak of SARS-CoV-2 has been declared a pandemic, which is a serious threat to human health. The disease was named coronavirus disease 2019 (COVID-19). Until now, several vaccines and a few drugs have been approved for the prevention and treatment for COVID-19. Recently, the effect of some macrolides including clarithromycin (CAM) on COVID-19 has attracted attention. CAM is known to have diverse effects including immunomodulatory and immunosuppressive effects, autophagy inhibition, steroid sparing effect, reversibility of drug resistance, antineoplastic effect, antiviral effect as well as bacteriostatic/bactericidal effect. Many patients with COVID-19 died due to an overwhelming response of their own immune system characterized by the uncontrolled release of circulating inflammatory cytokines (cytokine release syndrome [CRS]). This CRS plays a major role in progressing pneumonia to acute respiratory distress syndrome (ARDS) in COVID-19 patients. It is noteworthy that CAM can suppress inflammatory cytokines responsible for CRS and also has anti-SARS-CoV-2 effect. Considering the rapidly progressive global disease burden of COVID 19, the application of CAM for treating COVID-19 needs to be urgently evaluated. Recently, an open-labeled non-randomized trial using CAM for treating COVID-19 (ACHIEVE) was initiated in Greece in May, 2020. Its results, though preprint, indicated that CAM treatment of patients with moderate COVID-19 was associated with early clinical improvement and containment of viral load. Thus, treatment with CAM as a single agent or combined with other anti-SARS CoV-2 drugs should be tried for treating COVID-19. In this article, we discussed the significance and usefulness of CAM in treating COVID-19.

参考サイト PubMed: covid-19



バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
4月 14, 2020 バイオアソシエイツ

メルボルンの研究者らは、新型コロナウイルス(COVID-19)患者の1人から免疫反応をマッピングし、人体がウイルスと戦って感染から回復する能力を示した

メルボルンの研究者らは、オーストラリアで最初の新型コロナウイルス(COVID-19)患者の1人から免疫反応をマッピングし、ウイルスと戦って感染から回復する人体の能力を示した。 メルボルン大学とロイヤルメルボルン病院の合弁会社であるピータードハティ感染症研究所(ドハティ研究所)の研究者らは、COVID-19を呈し、入院を必要とする軽度から中程度の症状があった 40代の健康な女性の4つの異なる時点での血液サンプルをテストすることができた。2020年3月16日にNature…